At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 18 Apr 1997 No-Development-Reported for Cancer in USA (Unknown route)
- 29 Aug 1995 Preclinical development for Cancer in USA (Unknown route)